F. Brocard

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

C. Lepage, F. Ghiringhelli, J. Raoul, 2018, European journal of cancer.

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

I. Vergote, S. Pignata, I. Ray-Coquard, 2020, JAMA oncology.

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).

I. Treilleux, I. Ray-Coquard, O. Trédan, 2021, Gynecologic oncology.

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

L. Zelek, B. Chauffert, F. Scotté, 2021, The oncologist.

A retrospective cohort study to assess adjuvant concurrent chemoradiation (CCRT) compared to adjuvant radiation therapy (RT) in the treatment of grade 2 and 3 extremity soft tissue sarcomas.

J. Salleron, D. Peiffert, F. Marchal, 2017, Radiotherapy and Oncology.

CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients

A. Arnaud, T. Bachelot, R. Largillier, 2023, Breast Cancer.

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

A. Fourrier-Réglat, F. Tubach, J. Prevost, 2019, British Journal of Cancer.

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

F. Clatot, J. Ferrero, I. Moullet, 2020, Breast.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.

C. Lepage, P. Rougier, M. Hebbar, 2016 .